NCT02105168Unknown不适用
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 2,200
- 试验地点
- 1
- 主要终点
- Mutation rate on tumorous material
研究概览
简要总结
Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cytological or histological diagnosis of SCLC, NSCLC or melanoma
- •Patients age >/= 18 years old
- •Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated
- •If a biopsy is proposed, lesion lust be easily accessible
- •Signed informed consent
排除标准
- •Patients unable to follow the protocol
- •Consent refusal
研究组 & 干预措施
Experimental arm
Experimental
Blood sample Tumorous biopsy Healthy material sample
干预措施: Blood sample (Procedure)
Experimental arm
Experimental
Blood sample Tumorous biopsy Healthy material sample
干预措施: Tumorous biopsy (Procedure)
Experimental arm
Experimental
Blood sample Tumorous biopsy Healthy material sample
干预措施: Healthy material sample (Procedure)
结局指标
主要结局
Mutation rate on tumorous material
时间窗: Assessed at the time of inclusion
Assessed at the time of inclusion using tumorous material used for diagnosis
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCNon-small Cell Lung CancerNCT03130764Columbia University
招募中
不适用
Tumormarkers in diagnostics and follow up of lungcarcinomalungcancerlungcarcinoma1003866610029107NL-OMON47860Catharina-ziekenhuis1,500
已完成
Unknown
ongmerkerstudie<p>Lung carcinoma</p>10038666NL-OMON26180Catharina Ziekenhuis Eindhoven, NWO, Catharina Onderzoeksfonds, Roche Diagnostics Nederland1,500
已完成
不适用
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive TherapyCarcinoma, Non-Small-Cell LungNCT03740126Rigshospitalet, Denmark750
已完成
不适用
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With MelanomaMelanoma (Skin)NCT00004153University of Chicago106